Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $480 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals, maintaining a price target of $480.
October 08, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Vertex Pharmaceuticals, maintaining a price target of $480, indicating confidence in the company's stock performance.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for Vertex Pharmaceuticals' stock. This could lead to increased investor interest and buying pressure, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100